Sphera Funds Management’s BridgeBio Pharma BBIO Stock Holding History

Sphera Funds Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-130,000	Closed	-$6.75M	–	102
2025 Q3	$6.75M	Buy	+130,000	New	+$6.34M	1.42%	19
2024 Q3	–	Sell	-204,600	Closed	-$5.18M	–	121
2024 Q2	$5.18M	Buy	204,600 +154,600	+309%	+$4.23M	0.71%	47
2024 Q1	$1.55M	Buy	+50,000	New	+$1.7M	0.22%	87
2023 Q3	–	Sell	-130,000	Closed	-$2.24M	–	88
2023 Q2	$2.24M	Sell	130,000 -70,000	-35%	-$1.05M	0.35%	69
2023 Q1	$3.32M	Buy	+200,000	New	+$2.33M	0.55%	54

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sphera Funds Management's BBIO Position: Q1 2026 in Review

Sphera Funds Management increased its BridgeBio Pharma (BBIO) stake by 128% in Q1 2026, buying an estimated $9.97M and bringing the position to 245,246 shares worth $18.2M. The position accounts for 2.89% of the portfolio, ranked #6.

Sphera Funds Management first reported a position in BBIO in Q4 2020 and has held it in 15 quarters since. The position peaked at $24.8M in Q4 2024. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Sphera Funds Management held 245,246 shares of BridgeBio Pharma worth $18.2M as of Q1 2026.
Sphera Funds Management bought 137,500 BridgeBio Pharma shares in Q1 2026, an estimated $9.97M.
BridgeBio Pharma made up 2.89% of Sphera Funds Management's portfolio in Q1 2026, its #6 holding.
Sphera Funds Management first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 15 quarters since.
Sphera Funds Management's BridgeBio Pharma position peaked at $24.8M in Q4 2024.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.